McNicoll Lewis & Vlak Initiates Coverage on ImmunoCellular Therapeutics Ltd (IMUC)

By admin | 6 years ago

Research analysts at McNicoll Lewis & Vlak assumed coverage on shares of ImmunoCellular Therapeutics Ltd (NASDAQ: IMUC) in a report released on Tuesday. The firm set a “buy” rating on the stock.

IMUC has been the subject of a number of other recent research reports. Analysts at MLV & Co initiated coverage on shares of ImmunoCellular Therapeutics Ltd in a research note to investors on Tuesday. They set a “buy” rating and a $4.50 price target on the stock. Separately, analysts at Cowen initiated coverage on shares of ImmunoCellular Therapeutics Ltd in a research note to investors on Friday, February 17th. They set a “neutral” rating on the stock. Finally, analysts at Cowen initiated coverage on shares of ImmunoCellular Therapeutics Ltd in a research note to investors on Friday, February 17th. They set a “neutral” rating on the stock.

ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.

About the author